Literature DB >> 11244038

IgG Fc receptors.

J V Ravetch1, S Bolland.   

Abstract

Since the description of the first mouse knockout for an IgG Fc receptor seven years ago, considerable progress has been made in defining the in vivo functions of these receptors in diverse biological systems. The role of activating Fc gamma Rs in providing a critical link between ligands and effector cells in type II and type III inflammation is now well established and has led to a fundamental revision of the significance of these receptors in initiating cellular responses in host defense, in determining the efficacy of therapeutic antibodies, and in pathological autoimmune conditions. Considerable progress has been made in the last two years on the in vivo regulation of these responses, through the appreciation of the importance of balancing activation responses with inhibitory signaling. The inhibitory FcR functions in the maintenance of peripheral tolerance, in regulating the threshold of activation responses, and ultimately in terminating IgG mediated effector stimulation. The consequences of deleting the inhibitory arm of this system are thus manifested in both the afferent and efferent immune responses. The hyperresponsive state that results leads to greatly magnified effector responses by cytotoxic antibodies and immune complexes and can culminate in autoimmunity and autoimmune disease when modified by environmental or genetic factors. Fc gamma Rs offer a paradigm for the biological significance of balancing activation and inhibitory signaling in the expanding family of activation/inhibitory receptor pairs found in the immune system.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11244038     DOI: 10.1146/annurev.immunol.19.1.275

Source DB:  PubMed          Journal:  Annu Rev Immunol        ISSN: 0732-0582            Impact factor:   28.527


  534 in total

Review 1.  Functions of antibodies in the regulation of B cell responses in vivo.

Authors:  B Heyman
Journal:  Springer Semin Immunopathol       Date:  2001-12

2.  An unusual Fc receptor-related protein expressed in human centroblasts.

Authors:  Fabio Facchetti; Marina Cella; Silvana Festa; Daved H Fremont; Marco Colonna
Journal:  Proc Natl Acad Sci U S A       Date:  2002-03-12       Impact factor: 11.205

3.  Fcgamma receptor polymorphisms in populations in Ethiopia and Norway.

Authors:  L Van Den Berg; K M Myhr; B Kluge; C A Vedeler
Journal:  Immunology       Date:  2001-09       Impact factor: 7.397

4.  Identification of a family of Fc receptor homologs with preferential B cell expression.

Authors:  R S Davis; Y H Wang; H Kubagawa; M D Cooper
Journal:  Proc Natl Acad Sci U S A       Date:  2001-08-07       Impact factor: 11.205

5.  Immunoglobulin heavy chain constant regions regulate immunity and tolerance to idiotypes of antibody variable regions.

Authors:  Solveig Klaebo Reitan; Kristian Hannestad
Journal:  Proc Natl Acad Sci U S A       Date:  2002-05-28       Impact factor: 11.205

Review 6.  B cell inhibitory receptors and autoimmunity.

Authors:  Nicholas R Pritchard; Kenneth G C Smith
Journal:  Immunology       Date:  2003-03       Impact factor: 7.397

7.  A full complement of receptors in immune complex diseases.

Authors:  Jeffrey V Ravetch
Journal:  J Clin Invest       Date:  2002-12       Impact factor: 14.808

Review 8.  Inhibition of T cell responses by transferrin-coupled competitor peptides.

Authors:  Lolita Zaliauskiene; Rebecca L Fazio; Sunghyun Kang; Kerri Sparks; Casey T Weaver; Kurt R Zinn; James F Collawn
Journal:  Immunol Res       Date:  2002       Impact factor: 2.829

Review 9.  Diversity and duplicity: human FCgamma receptors in host defense and autoimmunity.

Authors:  Robert P Kimberly; Jianming Wu; Andrew W Gibson; Kaihong Su; Hongwe Qin; Xiaoli Li; Jeffrey C Edberg
Journal:  Immunol Res       Date:  2002       Impact factor: 2.829

10.  Enhancement of anti-tumor CD8 immunity by IgG1-mediated targeting of Fc receptors.

Authors:  Scott N Furlan; Rajakumar Mandraju; Travis Brewer; Kole Roybal; Ty Dale Troutman; Wei Hu; Noah W Palm; Arun Unni; Chandrashekhar Pasare
Journal:  MAbs       Date:  2014 Jan-Feb       Impact factor: 5.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.